Clinical Endocrinology Update 2024 Session Recordings
Image For Activity Cover
Availability
On-Demand
10 Courses
Expires on Dec 31, 2026
Cost
Member: $649.00
Non-Member: $999.00
In-Training Member: $589.00
Resident Member: $589.00
Resident Non-Member: $999.00
Credit Offered
27 AMA PRA Category 1 Credits
27 Participation Credits
  • Course Description
  • Target Audience
  • Accreditation Statement
  • Faculty and Disclosures
  • Recommended
CEU is the leading meeting for physicians and researchers looking for the information and skills needed to keep their endocrine practice up to date in patient care. CEU 2024 consists of 36 presentations:
  • Adrenal
  • Calcium & Bone
  • Diabetes
  • Female Reproduction
  • Lipid & Obesity
  • Male Reproduction
  • Pituitary
  • Thyroid
  • Transgender Care
Please Note: The recording of session "Lp(a) as a New Treatment Target in High-Risk CVD (S02)" is unavailable.
This activity is intended for Endocrinologists engaged in the care of patients with endocrine-related diseases in primary care, hospital, managed care organizations, ambulatory care.

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

A logo for a companyDescription automatically generatedAMA PRA Category 1 Credit
The Endocrine Society designates each activity in this course for a maximum of 27 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.


AMA PRA Category 1 Credits™ for the activities related to this material must be claimed by December 31, 2026

STATEMENT OF INDEPENDENCE 
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s Clinical Endocrinology Update Steering Committee. 

DISCLOSURE POLICY 
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 24 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable. 

The following CEU Committee Members reported relevant financial relationships:

  • Sara Ahmadi, MD: Editorial Board: American Thyroid Association; Editor: Endocrine Connection Journal; Research Support: Veraycyte.
  • Christine Burt Solorzano, MD: Research Support: Takeda; Grantee: NIH NICHD, Helmsley Trust; Trial Support: Pathway to Prevention
  • Anders L. Carlson, MD: Medical Director: Bright Health Group; Research Investigator: Insulet, Medtronic, Abbott, Dexcom, Sanofi, Novo Nordisk, Eli Lilly, UnitedHealth; Consulting/Advisory Board: Medtronic.
  • Matthew T. Drake, MD, PhD: Author: UpToDate.
  • Leonor Corsino, MD, MHS: Advisor: Latino Medical Student Association; Writing: American Board of Internal Medicine; Advisory Board: Project Access of Durham County, North Carolina Advisory Council; Consultant: GLG.
  • Adina Turcu, MD, MS: Grant: NIH (NIDDK, NHLBI), DDF; Investigator: CinCor; Writer: Endocrine Self-Assessment Program; Editor: JCEM Case Report.
  • Marcel Bartholomeus Twickler, MD, PhD: Working Group: "Health and Nutrition" in the "Hoge gezondheidsraad/Conseil Superieur de la Sante"; Investigator: PATRO Study; Editor: European Journal Clinical Investigation.

The following CEU steering committee members reported no financial relationships:

  • Shaishav Dhage, MBBS, DNB(Medicine), MRCP, MD; Elizabeth Harris, MD; and Beth Tupta, NP-C.


Disclosure information for presenters is included in their individual recorded presentations.

The Endocrine Society staff involved in the development of this CME activity reported no relevant financial relationships.

The relevant financial relationships listed for these individuals has been mitigated and there are no other relevant financial relationships with ineligible companies for those with the ability to control the content for this activity.

   
     EndoCareers | Contact Us | Privacy Policy | Terms of Use CONNECT WITH US                
       © 2021 Copyright Endocrine Society. All rights reserved.
2055 L Street NW, Suite 600 | Washington, DC 20036      
 202.971.3636 | 888.363.6274
      
   
Android App Download IOS App Download Powered By